PTPRC and colorectal carcinoma: Moreover, the above-mentioned report on gastrointestinal tumors [5] described that in 38.3% (18/47) of patient-derived xenograft tumor models in colorectal carcinoma (CRC) and 10.8% (12/37) in pancreatic ductal adenocarcinoma (PDAC) exhibited CD45 + CD20 + B-lymphocyte proliferation, while EBV-derived RNA was detectable in the CD45 + compartment of 66.7% (12/18) of the CRC cases and in 100% (12/12) of the PDAC tumors.